Zeiss Pharmaceuticals is a finished-dose manufacturer based in India. It appears in 27 regulatory filings across 5 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), NAFDAC (NG) and MINSA (CR). Its GMP standing is certified by FDA (GH). Customs aggregates show $870K of exports covering 59 molecules to 7 destinations in 2025.
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 9 | None |
| NAFDAC (NG) | 8 | None |
| MINSA (CR) | 7 | None |
| UZPHARM (UZ) | 2 | None |
| DAV (Vietnam) | 1 | None |
| FDA (GH) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $558K | 4 |
| 2025 | Not reported | $870K | 7 |
| 2024 | Not reported | $797K | 7 |
| 2023 | Not reported | $1.0M | 5 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Beyond the filing counts above, the public registers hold no plant, inspection or portfolio detail for this company as at 9 July 2026. We report that as a gap rather than inferring an answer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Zeiss Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.